New combo therapy aims to tame Hard-to-Treat myeloma
NCT ID NCT07093554
First seen Jan 07, 2026 · Last updated May 15, 2026 · Updated 23 times
Summary
This study tests a two-step treatment for people with multiple myeloma that has come back or stopped responding to other therapies. First, patients receive a drug called talquetamab to help control the cancer, followed by a one-time infusion of their own modified immune cells (cilta-cel). The main goal is to see if this approach is safe and feasible for about 31 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Froedtert & the Medical College of Wisconsin
RECRUITINGMilwaukee, Wisconsin, 53226, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.